Preview

User

Not a user? Register with this site Forgot your password?

Problems of Endocrinology

Advanced search

Results of growth hormone substitution therapy in children with brain tumours

https://doi.org/10.14341/probl201359219-25

Abstract

Aim of the study. To estimate the effectiveness and safety of substitution therapy with growth hormone (GH) in children with various brain tumours. Materials and methods. The study involved 68 patients admitted to N.N. Burdenko Institute of Neurosurgery between 2001 and 2011 including 35 ones with craniopharyngioma, 18 with medulloblastoma, and 15 with germ cell tumours (GCT) in the chiasmosellar region. All patients suffered growth hormone insufficiency and received GH replacement therapy. Their antropometric characteristics (height and growth rate) and IGF-1 levels were measured before, 6 and 12 months after the onset of the treatment. The doses of GH varied from 0.03 to 0.034 mg/kg/day. Results. The substitution therapy with GH resulted in an increase of the growth rate in patients with craniopharyngioma from 2.3±1.6 to 9.4±1.9 cm/year (p<0.001), in those with GCT from 1.2±0.9 to 7.4±2.6 cm/year (p=0.01), and in patients with medulloblastoma from 2.3±1.5 to 6.2±2.6 cm/year (p<0.01). The growth rate in patients treated by spinal irradiation was lower than that in those given no such treatment (6.0±2.3 cm/year and 9.2±2.1 cm/year respectively; p<0.001). The tumour recurred in eight of 35 (23%) patients with craniopharyngioma during GH therapy. The frequency of relapses was not significantly different from that in patients who did not receive growth hormone. Patients with medulloblastoma and GCT did not develop relapses. No adverse reactions to GH therapy were documented in this study.

References

1. Birch J.M., Parkin D.M., Stiller C.A., Draper G.J. Manchester children's tumour registry 1954-1970 and 1971-1983; International incidence of childhood cancer. Lyon: IARC Scientific publications 1988; 299-304.

2. Sklar C.A. Childhood brain tumors. J Pediatr Endocrinol Metabol 2002; 669-673.

3. Gurney J.G., Kadan-Lottick N.S., Packer R.J., Neglia J.P., Sklar C.A., Punyko J.A., Stovall M., Yasui Y., Nicholson H.S., Wolden S., McNeil D.E., Mertens A.C., Robison L.L. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors. Cancer 2003; 97: 663-673.

4. Мазеркина Н.А. Эндокринные нарушения после комплексного лечения злокачественных опухолей хиазмально-селлярной области и задней черепной ямки у детей: Автореф. дис. ... д-ра мед. наук. М 2007.

5. Мазеркина Н.А., Коновалов А.Н., Горелышев С.К., Семенова Ж.Б., Краснова Т.С., Тенедиева В.Д. Эндокринные нарушения при краниофарингиомах у детей: Зависимость от локализации опухоли. Журн вопр нейрохир 2008; 23-29.

6. Shalet S.M., Whitehead E., Chapman A.J., Beardwell C.G. The effects of growth hormone therapy in children with radiation-induced growth hormone deficiency. Acta Paediatr Scand 1981; 70: 81-86.

7. Jostel A., Shalet S.M. Childhood brain tumours and growth hormone treatment. Review; Growth hormone therapy in pediatrics - 20 years of kigs. Bazel: Karger 2007; 240-249.

8. Packer R.J., Goldwein J., Nicholson H.S., Vezina L.G., Allen J.C., Ris M.D., Muraszko K., Rorke L.B., Wara W.M., Cohen B.H., Boyett J.M. Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A children's cancer group study. J Clin Oncol 1999; 17: 2127-2136.

9. Adan L., Sainte-Rose C., Souberbielle J.C., Zucker J.M., Kalifa C., Brauner R. Adult height after growth hormone (gh) treatment for growth hormone deficiency due to cranial irradiation. Med Pediatr Oncol 2000; 34: 14-19.

10. Herber S.M., Dunsmore I.R., Milner R.D. Final stature in brain tumours other than craniopharyngioma: Effect of growth hormone. Horm Res 1985; 22.

11. Lannering B., Albertsson-Wikland K. Improved growth response to gh treatment in irradiated children. Acta Paediatr Scand 1989; 78: 562-567.

12. Leung W., Rose S.R., Zhou Y., Hancock M.L., Burstein S., Schriock E.A., Lustig R., Danish R.K., Evans W.E., Hidson M.M., Pui C.H. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 2959-2964.

13. Vassilopoulou S., Klein M.G., Moore B.D., Reid H.L., Ater J., Zietz H.A. Efficacy of growth hormone replacement therapy in children with organic growth hormone deficiency after cranial irradiation. Horm Res 1995; 43: 1888-1935.

14. Xu W., Janss A., Moshang T. Adult height and adult sitting height in childhood medulloblastoma survivors. J Clin Endocrinol Metabol 2003; 88: 4677-4681.

15. Ranke M.B., Price D.A., Wilton P. Growth hormone treatment in children with malignant tumours in kigs; Growth hormone therapy in kigs: 10 years experience. Heidelberg (Germany): Johan Ambrosis Barth-Verlag 1999; 159-174.

16. Ranke M.B., Price D.A., Reiter E.O. Growth hormone therapy in pediatrcs - 20 years of kigs. Basel: Karger 2007.

17. Shalet S.M., Gibson B., Swindell R., Pearson D. Effects of spinal irradiation on growth. Arch Dis Child 1987; 62: 461-464.

18. Sulmont V., Brauner R., Fontoura M., Rappaport R. Response to growth hormone treatment and final height after cranial or craniospinal irradiation. Acta Paediatr Scand 1990; 79: 542-549.

19. Clayton P.E., Shalet S.M. The evolution of spinal growth after irradiation. Clin Oncol 1991; 3: 220-222.

20. Oberfield S.E., Soranno D., Nirenberg A., Heller G., Allen J.C., David R., Levine L.S., Sklar C.A. Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adoles Med 1996; 150: 589-592.

21. Xu W., Janss A., Packer R.J., Phillips P., Goldwein J., Moshang T.Jr. Endocrine outcome in children with medulloblastoma treated 18 gy of craniospinal radiation therapy. Neurol Oncol 2004; 6: 113-118.

22. Ranke M.B., Price D.A., Lindberg A., Wilton P., Darendeliler F., Reiter E.O. Final height in children with medulloblastoma treated with growth hormone. Horm Res 2005; 64: 28-34.

23. Brownstein C.M., Mertens A.C., Mitby P.A., Stovall M., Qin J., Heller G., Robison L.L., Sklar C.A. Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survival study. J Clin Endocrinol Metabol 2004; 89: 4422-4427.

24. Ogilvy-Stuart A.L., Clayton P.E., Shalet S.M. Cranial irradiation and early puberty. J Clin Endocrinol Metabol 1994; 78: 1282-1287.

25. Gleeson H.K., Stoeter R., Ogilvy-Stuart A.L., Gattamaneni H.R., Brennan B.M., Shalet S.M. Improvements in final height over 25 years in growth hormone (gh)-deficient childhood survivors of brain tumors receiving gh replacement. J Clin Endocrinol Metabol 2003; 88: 3682-3689.

26. LeRoith D., Roberts C.T. The insulin-like growth factor cyctem and cancer. Cancer Lett 2003; 195: 127-137.

27. Darendeliler F. Safety of growth hormone treatment. J Clin Res Ped Endocrin 2009; 36-43.

28. Ogilvy-Stuart A.L., Gleeson H. Cancer risk following growth hormone use in childhood. Drug Safety 2004; 27: 369-382.

29. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-i and prostate cancer risk: a prospective study. Science 1998; 279: 563-566.

30. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., Pollak M. Circulating concentrations of insulin-like growth factor-i and risk of breast cancer. Lancet 1998; 351: 1393-1396.

31. Zadik Z., Estrov Z., Karov Y., Hahn T., Barak Y. The effect of growth hormone and igf-i on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission- a preliminary report. J Pediatr Endocrinol 1993; 6: 79-83.

32. Al-Mefty O., Topsakal C., Pravdenkova S., Sawyer J.R., Harrison M.J. Radiation-induced meningiomas: Clinical, pathological, cytokinetic, and cytogenetic characteristics. J Neurosurg 2004; 100: 1002-1013.

33. Amirjamshidi A., Abbassioun K. Radiation-induced tumors of the central nervous system occurring in childhood and adolescence. Four unusual lesions in three patients and a review of the literature. Childs Nerv Syst 2000; 16: 390-397.

34. de Vathaire F., Hawkins M., Campbell S., Oberlin O., Raquin M.A., Schlienger J.Y., Shamsaldin A., Diallo I., Bell J., Grimaud E., Hardiman C., Lagrange J.L., Daly-Schveitzer N., Panis X., Zucker J.M., Sancho-Garnier H., Eschwege F., Chavaudra J., Lemerle J. Second malignant neoplasms after a first cancer in childhood: Temporal pattern of risk according to type of treatment. Br J Cancer 1999; 79: 1884-1893.

35. Moshang T.Jr., Rundle A.C., Graves D.A., Nickas J., Johanson A., Meadows A. Brain tumor recurrence in children treated with growth hormone: The national cooperative growth study experience. J Pediatr 1996; 128: S4-S7.

36. Swerdlow A.J., Reddingius R.E., Higgins C.D., Spoudeas H.A., Phipps K., Qiao Z., Ryder W.D., Brada M., Hayward R.D., Brook C.G., Hindmarsh P.C., Shalet S.M. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metabol 2000; 85: 4444-4449.

37. Price D.A., Wilton P., Jonsson P., Albertsson-Wikland K., Chatelain P., Cutfield W., Ranke M.B. Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: An analysis of the pharmacia and upjohn international growth database (kigs) from 1988 to 1996. Horm Res 1998; 49: 91-97.

38. Семенова Ж.Б. Гистобиология краниофарингиом и особенности течения заболевания: Автореф. дис. ... д-ра мед. наук. М 2000.

39. Matsutani M., Sano K., Takakura K., Fujimaki T., Nakamura O., Funata N., Seto T. Primary intracranial germ cell tumors: A clinical analysis of 153 histologically verified cases. J Neurosurg 1997; 86: 446-455.

40. Packer R.J., Boyett J.M., Janss A.J., Stavrou T., Kun L., Wisoff J., Russo C., Geyer R., Phillips P., Kieran M., Greenberg M., Goldman S., Hyder D., Heideman R., Jones-Wallace D., August G.P., Smith S.H., Moshang T. Growth hormone replacement therapy in children with medulloblastoma: Use and effect on tumor control. J Clin Oncol 2001; 19: 480-487.


Review

For citations:

Mazerkina N.A., Gorelyshev S.K., Zheludkova O.G., Ozerov S.S., Kobiakov G.L., Kholodov B.V. Results of growth hormone substitution therapy in children with brain tumours. Problems of Endocrinology. 2013;59(2):19-25. https://doi.org/10.14341/probl201359219-25

Views: 654


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

11, Dm. Ul’yanova str., Moscow, Russian Federation, 117292

Processing of personal data
supported by NEICON (Elpub lab)